Zobrazeno 1 - 10
of 126
pro vyhledávání: '"R. F. Ozols"'
Publikováno v:
International Journal of Gynecologic Cancer. 13:149-155
Mature results from GOG158 have clearly established carboplatin and paclitaxel as an effective and well-tolerated standard regimen, providing a basis for the reference arm in GOG0182-ICON5, an ongoing multiarmed phase III trial of the Gynecologic Can
Publikováno v:
International Journal of Gynecologic Cancer. 13:735-740
Mature results from GOG158 have clearly established carboplatin and paclitaxel as an effective and well tolerated standard regimen, providing a basis for the reference arm in GOG0182-ICON5, an ongoing multiarmed phase III trial of the Gynecologic Can
Autor:
R F Ozols
Publikováno v:
Journal of Clinical Oncology. 15:2177-2180
HER-2/neu as a therapeutic target in non-small cell lung cancer, prostate cancer, and ovarian cancer
Publikováno v:
Seminars in oncology. 27(6 Suppl 11)
HER-2/neu is overexpressed in most epithelial malignancies. Lung cancer, prostate cancer, and ovarian cancer are common epithelial tumors in which clinical trials are currently in progress to explore the potential therapeutic role for monoclonal anti
Autor:
J S, Berek, K, Bertelsen, A, du Bois, M F, Brady, J, Carmichael, E A, Eisenhauer, M, Gore, S, Grenman, T C, Hamilton, S W, Hansen, P G, Harper, G, Horvath, S B, Kaye, H J, Lück, B, Lund, W P, McGuire, J P, Neijt, R F, Ozols, M K, Parmar, M J, Piccart-Gebhart, R, van Rijswijk, P, Rosenberg, G J, Rustin, C, Sessa, J T, Thigpen, C, Tropé, M K, Tuxen, I, Vergote, J B, Vermorken, P H, Willemse
Publikováno v:
Gynecologie, obstetriquefertilite. 28(7-8)
Autor:
R F, Ozols
Publikováno v:
Seminars in oncology. 27(3 Suppl 7)
The activity of paclitaxel (Taxol; Bristol-Myers Squibb Company, Princeton, NJ) in advanced ovarian cancer, both as a single agent and in combination chemotherapy, has been demonstrated in numerous phase I/II trials. Paclitaxel/platinum combinations
Autor:
R F, Ozols
Publikováno v:
Seminars in oncology. 27(3 Suppl 7)
Autor:
R F, Ozols
Publikováno v:
Seminars in oncology. 26(6 Suppl 18)
Prospective randomized trials have established carboplatin plus paclitaxel as the preferred combination chemotherapy for patients with advanced ovarian cancer. However, clinical issues remain to be determined regarding the use of this regimen. These
Publikováno v:
Cancer chemotherapy and biological response modifiers. 18
Autor:
R F, Ozols
Publikováno v:
Seminars in oncology. 27(1 Suppl 2)
Epithelial ovarian cancer remains the number one gynecologic killer in the Western world. The standard therapeutic approach for patients with advanced-stage epithelial ovarian cancer has been cytoreductive surgery followed by combination chemotherapy